Antibody therapy was in the media spotlight for the first time when it was administered to Donald Trump (74). The then president of the United States received an injection with a cocktail of antibodies from the biotech company Regeneron, which had not yet been formally approved for treatment. Roche pharmaceutical company Basel is also involved in the development. The antibodies are designed to prevent the virus from spreading throughout the body. Thus preventing the course of dangerous or fatal disease.
The Federal Council wants to arm itself with regard to the supply of important and promising drugs against Covid-19, as announced yesterday in Bern. So-called monoclonal combination antibody therapies will soon be available in Switzerland. Until health insurers take over the costs, the federal government wants to pay for these treatments to be funded.
It is administered once intravenously
These drugs, which are given intravenously once, prevent the virus from entering the cell and, according to preliminary studies, significantly reduce the risk of developing the disease. If it is used in an early stage of the disease. The model and the basis are the antibodies obtained from human plasma that have survived Covid-19.
In the USA and Italy, for example, there have already been emergency approvals for such drugs. Medicines containing monoclonal antibodies have been around since the 1990s. Until now, it has been used mostly against cancer or autoimmune diseases. (pbe / SDA)
The ex is about to vent: Trump’s coronavirus pathway was much worse than expected(00:39)
Publish date: 04/15/2021, 1:47 pm
Last updated: April 15, 2021, 14 minutes ago